Treatment
STERILE
Patients in the GDLM group received a GDLM injection of 5 mL (active ingredient GDLM, 25 mg) once daily via intravenous infusion for 14 consecutive days. Patients in the placebo group received a GDLM mimic injection (physiological saline) of 5 mL once daily via intravenous infusion for 14 consecutive days. Both the GDLM and placebo were diluted in 250 mL of sterile 0.9% sodium chloride injection. Treatment was dispensed within 48 hours after symptoms. Treatment was discontinued when the patients were discharged prior to 14 days. All of the patients were followed up to day 90 after randomization.